Search

Your search keyword '"Martín-Rabadán, Pablo"' showing total 8 results
Start Over Author "Martín-Rabadán, Pablo" Publisher elsevier
8 results on '"Martín-Rabadán, Pablo"'

2. Contributors

Author

Alangaden, George J., primary, Aldape, Michael J., additional, Allardet-Servent, Jérôme, additional, Allen, Upton D., additional, Ammerlaan, Heidi S.M., additional, Angelakis, Emmanouil, additional, Artenstein, Andrew, additional, Asboe, David, additional, Asiedu, Kingsley B., additional, Atherton, John C., additional, Aw, Tar-Ching, additional, Baid-Agrawal, Seema, additional, Bailey, Robin, additional, Bandel, Christopher, additional, Barie, Philip S., additional, Barillo, David J., additional, Bart, Pierre-Alexandre, additional, Bayston, Roger, additional, Beard, C. Ben, additional, Beeching, Nick J., additional, Bégué, Rodolfo E., additional, Benhamou, Yves, additional, Benson, Constance A., additional, Berbari, Elie F., additional, Berendt, Anthony R., additional, Bhatta, Madhav P., additional, Bille, Jacques, additional, Bitnun, Ari, additional, Black, Finn T., additional, Blair, Iain, additional, Blanche, Stéphane, additional, Bleck, Thomas P., additional, Bleeker-Rovers, Chantal P., additional, Bleijenberg, Gijs, additional, Bloch, Karen C., additional, Bonten, Marc J.M., additional, Boucher, Charles A.B., additional, Bourayou, Rafik, additional, Bouza, Emilio S., additional, Bowie, William R., additional, Brause, Barry D., additional, Brisse, Sylvain, additional, Britton, Warwick, additional, Brook, Itzhak, additional, Brown, David W.G., additional, Brun-Buisson, Christian, additional, Brust, James C.M., additional, Bryant, Amy E., additional, Bryskier, André, additional, Buller, R. Mark L, additional, Bush, Karen, additional, Calandra, Thierry, additional, Cameron, D. William, additional, Caraël, Michel, additional, Carr, Michael J., additional, Casas, Inmaculada, additional, Chambers, Stephen T., additional, Chiller, Katarina G., additional, Chiller, Tom M., additional, Chiodini, Peter L., additional, Chopra, Ian, additional, Chu, Anthony C., additional, Chung, Kevin K., additional, Clark, Benjamin M., additional, Clumeck, Nathan, additional, Cockerell, Clay J., additional, Cohen, Jonathan, additional, Collinge, John, additional, Conlon, Christopher P., additional, Corey, G. Ralph, additional, Cross, Alan, additional, Cross, John H., additional, Currier, Judith, additional, Curtis, Carmel M., additional, Dallabetta, Gina, additional, Davidson, Robert N., additional, Davies, Jane, additional, Day, Jeremy, additional, Day, Nicholas P.J., additional, De Gascun, Cillian F., additional, de Wit, Stéphane, additional, Delmont, Jean, additional, Dennis, David T., additional, Diemert, David J., additional, Doganay, Mehmet, additional, Doherty, Tom, additional, Dolecek, Christiane, additional, Donati, Stéphane Y., additional, Dondorp, Arjen M., additional, Doudier, Barbara, additional, Drancourt, Michel, additional, Drekonja, Dimitri M., additional, Drew, Richard H., additional, Duker, Jay S., additional, Dummer, J. Stephen, additional, Edwards, Charles N., additional, Ekkelenkamp, Miquel B., additional, Enright, Mark C., additional, Epstein, Paul R., additional, Erard, Veronique, additional, Eziefula, Alice Chijioke, additional, Feinberg, Mark B., additional, Fenollar, Florence, additional, Fenwick, Alan, additional, Fernandez, Luis, additional, Fierer, Joshua, additional, Finch, Roger G., additional, Flexner, Charles W., additional, Fluit, Ad C., additional, Ford-Jones, Elizabeth Lee, additional, Fournier, Pierre-Edouard, additional, Fraser, Victoria, additional, French, Martyn A., additional, Friedland, Jon S., additional, Fritz, Joseph M., additional, Furuya, E. Yoko, additional, Gage, Kenneth L., additional, Garcia, Lynne S., additional, Gastañaduy, Arturo S., additional, Ghanem, Khalil G., additional, Giannella, Maddalena, additional, Glaser, Carol A., additional, Glesby, Marshall J., additional, Glover, Sarah, additional, Glupczynski, Youri, additional, Gnann, John W., additional, Goddard, Andrew F., additional, Goldstein, Ellie J.C., additional, González, Iveth J., additional, Gorbach, Sherwood L., additional, Gottstein, Bruno, additional, Gowda, Ravi, additional, Grabenstein, John D., additional, Grange, John M., additional, Green, Michael D., additional, Green, Stephen T., additional, Greenblatt, Danielle T., additional, Greenwood, Brian, additional, Gregson, Aric L., additional, Groll, Andreas H., additional, Gupta, Aditya K., additional, Gwee, Kok-Ann, additional, Hall, William, additional, Hammer, Scott M., additional, Handa, Sajeev, additional, Hanfelt-Goade, Diane, additional, Harari, Alexandre, additional, Harris, Marianne, additional, Hartman, Barry J., additional, Hay, Roderick J., additional, Henderson, David K., additional, Hensley, Lisa E., additional, Herbert, Luke, additional, Hill, David R., additional, Hills, Timothy J., additional, Hinze, John David, additional, Hirsch, Hans H., additional, Hirschel, Bernard, additional, Hoepelman, Andy I.M., additional, Holland, Steven M., additional, Horgan, Mary M., additional, Howe, Robin, additional, Hughes, James M., additional, Hull, Mark W., additional, Inderlied, Clark B., additional, Ison, Michael G., additional, Jenks, Peter J., additional, Johnson, James R., additional, Jones, Theodore, additional, Kanno, Mettassebia, additional, Kauffman, Carol, additional, Kelly, Patrick, additional, Kendler, Jason S., additional, Keynan, Yoav, additional, Khan, Ali S., additional, Kho, Grace T., additional, Kinghorn, George R., additional, Klapper, Paul E., additional, Kluytmans, Jan AJW, additional, Kok, Menno, additional, Koné-Paut, Isabelle, additional, Krieger, John N., additional, Kroes, Aloys C.M., additional, Kroon, Frank P., additional, Kubin, Christine J., additional, La Rosa, Alberto M., additional, Lalani, Tahaniyat, additional, Lalloo, David G., additional, Lambert, Harold, additional, Landraud, Luce, additional, Lawn, Stephen D., additional, Pharm, Phillipe Lehours, additional, Leone, Marc, additional, Levi, Itzchak, additional, Levitt, Alexandra M., additional, Lindquist, H. D. Alan, additional, Lloyd, Graham, additional, Looney, David J., additional, Lowy, Franklin D., additional, Luft, Benjamin J., additional, Lynn, William A., additional, Macielag, Mark J., additional, Mackowiak, Philip A., additional, MacPherson, Paul A., additional, Maghraoui-Slim, Valérie, additional, Main, Janice, additional, Mallet, Vincent, additional, Mangino, Julie E., additional, Manuel, Oriol, additional, Marchetti, Oscar, additional, Marks, Kristen, additional, Marr, Kieren A., additional, Martin, Claude, additional, Martín-Rabadán, Pablo, additional, Martinez, Augusto Julio, additional, Mascini, Ellen M., additional, Mayer, Kenneth H., additional, McCormick, Joseph B., additional, McGready, Rose, additional, McKendrick, Michael W., additional, Mead, Simon, additional, Mégraud, Francis, additional, Meheus, André Z., additional, Meintjes, Graeme, additional, Michaels, Marian G., additional, Miles, Michael, additional, Miller, Alastair, additional, Mimiaga, Matthew J., additional, Mingeot-Leclercq, Marie-Paule, additional, Mitchell, Thomas G., additional, Moise, Pamela A., additional, Montaner, Julio, additional, Moore, Caroline B., additional, Moreillon, Philippe, additional, Morgan-Capner, Peter, additional, Montessori, Valentina, additional, Moss, Peter, additional, Muñoz, Patricia, additional, Naber, Kurt G., additional, Nakhla, Sammy, additional, Narain, Jai P., additional, Nathwani, Dilip, additional, Newton, Paul, additional, Nguyen, Chinh, additional, Nicolle, Lindsay E., additional, Niederman, Michael S., additional, Noel, Gary J., additional, Norrby, S. Ragnar, additional, Nosten, François, additional, Notarangelo, Luigi Daniele, additional, Nyirjesy, Paul, additional, O'Connell, P. Ronan, additional, Odorico, Jon S., additional, Ong, Edmund L.C., additional, Opal, Steven M., additional, Ormerod, L. Peter, additional, Osmon, Douglas R., additional, Ottesen, Eric A., additional, Palacios, Gustavo, additional, Pantaleo, Giuseppe, additional, Papazian, Laurent, additional, Parola, Philippe, additional, Pascual, Manuel A., additional, Patrozou, Eleni, additional, Paya, Carlos, additional, Peacock, Sharon J., additional, Pechère, Jean-Claude, additional, Perkins, Mark D., additional, Peters, Barry, additional, Pfyffer, Gaby E., additional, Pham, Paul A., additional, Piot, Peter, additional, Placko-Parola, Geraldine, additional, Pol, Stainslas, additional, Posfay-Barbe, Klara M., additional, Powderly, William G., additional, Pozniak, Anton, additional, Prod'hom, Guy, additional, Quinn, Thomas C., additional, Rahn, Daniel W., additional, Rana, Aadia I., additional, Raoult, Didier, additional, Raz, Raul, additional, Razonable, Raymund, additional, Read, Robert C., additional, Reynolds, Stephen J., additional, Richardson, Malcolm D., additional, Robinson, Christopher C., additional, Rooijakkers, Suzan H.M., additional, Rosenbluth, Daniel, additional, Rosenzweig, Sergio D., additional, Rovery, Clarisse, additional, Rubin, Robert H., additional, Rubinovitch, Bina, additional, Rubins, Kathleen H., additional, Rubinstein, Ethan, additional, Ryan, Greg, additional, Ryder, Stephen, additional, Safren, Steven, additional, Sahasrabuddhe, Vikrant V., additional, Saikku, Pekka A.I., additional, Sakoulas, George, additional, Salazar, Juan Carlos, additional, Salvaggio, Michelle R., additional, Schaffer, Kirsten, additional, Schmitz, Franz-Josef, additional, Schooley, Robert T., additional, Schumacher, Richard-Fabian, additional, Scrimgeour, Euan M., additional, Seddon, James, additional, Seifert, Harald, additional, Serjeant, Graham R., additional, Sha, Beverly E., additional, Shah, Keerti V., additional, Shapiro, Daniel S., additional, Sheehan, Gerard, additional, Shoham, Shmuel, additional, Simmons, Cameron P., additional, Simonsen, Kari A., additional, Singh, Neeraj, additional, Slack, Mary P.E., additional, Sobel, Jack D., additional, Sopirala, Madhuri M., additional, Spacek, Lisa A., additional, Sriskandan, Shiranee, additional, Stanley, Samuel L., additional, Steckelberg, James M., additional, Stephenson, Iain, additional, Stevens, Dennis L., additional, Straus, Walter L., additional, Sturm, Willem, additional, Summerbell, Richard C., additional, Susa, Joseph S., additional, Tabrizi, Sarah J., additional, Tack, Marc A., additional, Taplitz, Randy, additional, Tebas, Pablo, additional, Temmerman, Marleen, additional, Thijsen, Steven F.T., additional, Thomas, Lora D., additional, Thomson, Gail, additional, Thwaites, Guy E., additional, Tirelli, Umberto, additional, Tolkoff-Rubin, Nina E., additional, Tønjum, Tone, additional, Torriani, Francesca J., additional, Townsend, Gregory C., additional, Masó, Gloria Trallero, additional, Tulkens, Paul M., additional, Tunkel, Allan R., additional, Vaccher, Emanuela, additional, Vallet-Pichard, Anaïs, additional, Van Bambeke, Françoise, additional, van de Beek, Diederik, additional, van der Meer, Jos W.M., additional, van Loon, Anton M., additional, van Putten, Jos, additional, Vaudaux, Bernard P., additional, Vermund, Sten H., additional, Verstraelen, Hans, additional, Verweij, Paul, additional, Viscidi, Raphael P., additional, Visvanathan, Kumar, additional, Visvesvara, Govinda S., additional, von Seidlein, Lorenz, additional, Wagenlehner, Florian M.E., additional, Wahl-Jensen, Victoria, additional, Walsh, Thomas J., additional, Warhurst, David C., additional, Warnock, David W., additional, Warrell, David A., additional, Warrell, Mary J., additional, Warris, Adilia, additional, Weber, Rainer, additional, Weidner, Wolfgang, additional, Weston, Vivienne C., additional, Whimbey, Estella, additional, Whitby, Michael, additional, White, Peter J., additional, Whitty, Christopher J.M., additional, Willems, Rob J.L., additional, Williams, Emrys, additional, Wilson, Cara, additional, Wilson, Mary E., additional, Winn, Richard E., additional, Winthrop, Kevin L., additional, Wiselka, Martin J., additional, Wisplinghoff, Hilmar, additional, Wolfe, Cameron R., additional, Wood, Robin, additional, Wright, Natalie, additional, Yankaskas, James R., additional, Zaidi, Najam A., additional, Zenilman, Jonathan M., additional, Zhang, Yaobi, additional, Zuckerman, Arie J., additional, Zuckerman, Jane Nicola, additional, and Zumla, Alimuddin, additional

Published
2010
Full Text
View/download PDF

3. ΔF659 and F659S substitutions at the HS1 of FKS2 gene, along with E655A and W715L upstream and downstream substitutions, correlate with high ibrexafungerp MICs against Candidaglabrata.

Author

Mesquida A, Díaz-García J, Sánchez-Carrillo C, Martín-Rabadán P, Alcalá L, Muñoz P, Escribano P, and Guinea J

Subjects
Anidulafungin pharmacology, Drug Resistance, Fungal genetics, Genes, Fungal, Glycosides pharmacology, Microbial Sensitivity Tests, Triterpenes pharmacology, Antifungal Agents pharmacology, Candida glabrata drug effects, Candida glabrata genetics, Echinocandins pharmacology
Abstract

Objectives: Ibrexafungerp is a new inhibitor of Candida spp glucan synthase. We previously set the ibrexafungerp wild-type upper limit (wtUL) against Candida glabrata. We here assessed which FKS2 gene substitutions confer an ibrexafungerp non-wild-type phenotype in C. glabrata isolates., Methods: We studied a set of C. glabrata (n = 34) isolates showing resistance to micafungin and anidulafungin (n = 28) or only to anidulafungin (n = 6) and harbouring 10 different FKS2 gene substitutions. Antifungal susceptibility to ibrexafungerp was tested according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) E.Def 7.3.2 procedure and isolates were considered ibrexafungerp non-wild type according to the statistical wtUL (minimum inhibitory concentration [MIC] ≥2) or visual wtUL (MIC ≥4)., Results: Ibrexafungerp MICs against the isolates ranged from 0.06 to 4 mg/L. Four FKS2 gene substitutions (ΔF659, F659S, E655A, and W715L) were exclusively found in isolates showing an ibrexafungerp MIC above the statistical wtUL (≥2 mg/L) whereas isolates harbouring other substitutions were found to be ibrexafungerp wild type. The use of the visual wtUL (MIC ≥4 mg/L) bisected the population of isolates harbouring such substitutions., Discussion: C. glabrata isolates showing an ibrexafungerp MIC ≥2 mg/L may be considered non-wild type and are prone to harbour ΔF659, F659S, E655A, and W715L substitutions at the FKS2 gene. It is worth noting that substitutions ΔF659 and F659S were located at the beginning of the HS1 of FKS2 gene of C. glabrata. The role of other substitutions on conferring a non-wild-type phenotype to ibrexafungerp is not well elucidated., (Copyright © 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.)

Published
2022
Full Text
View/download PDF

4. Revisiting nocardiosis at a tertiary care institution: Any change in recent years?

Author

Galar A, Martín-Rabadán P, Marín M, Cercenado E, Sánchez-Carrillo C, Valerio M, Bouza E, and Muñoz P

Subjects
Adult, Aged, Aged, 80 and over, Chronic Disease, Cohort Studies, Drug Resistance, Multiple, Bacterial, Female, Humans, Incidence, Male, Middle Aged, Nocardia genetics, Nocardia Infections drug therapy, Nocardia Infections microbiology, Respiratory Tract Infections drug therapy, Respiratory Tract Infections microbiology, Retrospective Studies, Risk Factors, Spain epidemiology, Tertiary Healthcare, Adrenal Cortex Hormones therapeutic use, Anti-Bacterial Agents pharmacology, Neoplasms drug therapy, Nocardia isolation & purification, Nocardia Infections epidemiology, Respiratory Tract Infections epidemiology
Abstract

Objective: To analyse relevant changes in incidence, clinical and microbiological characteristics of nocardiosis over the last 24 years at the current institution., Materials and Methods: The clinical records of patients with nocardiosis (2006-2018) were reviewed and then compared with a previous cohort (1995-2006). Nocardia isolates were identified by 5'-end-16S-rRNA-gene-PCR targeting the first 500 bp of the gene and sequencing. Susceptibility tests were determined by broth microdilution (CLSI guidelines)., Results: Forty-two patients (64.3% male) with nocardiosis were evaluated in the recent cohort: 51.2% had COPD, 43.9% were on corticosteroid therapy and 31.7% had cancer. The incidence of nocardiosis varied from 6.3 to 7.1/100,000 admissions (p = 0.62). There was a decrease in HIV patients (27% vs. 4.9%, p = 0.01) and solid organ transplantation (SOT) recipients (18.9% vs. 2 .4%, p = 0.01). Cases with pulmonary involvement had increased (70.3% vs. 90.5%, p = 0.04). Nocardia species were similar but the most common were N. cyriacigeorgica (32.4% vs. 40.5%, p = 0.49) and N. farcinica (24.3% vs. 14.3%, p = 0.39). Antibiotic resistance remained stable: cotrimoxazole (10.8% vs. 5.7%, p = 0.68), imipenem (5.4% vs. 5.6%, p = 1.0); amikacin and linezolid were 100% active. No differences were found in breakthrough nocardiosis (21.6% vs. 9.8%, p = 0.21) or related mortality (21.6% vs. 21.4%, p = 1.0). The multivariate analysis confirmed that nocardiosis caused by N. farcinica is a risk factor for poor outcome (p = 0.045)., Conclusions: Nocardiosis incidence has remained stable. It mainly affected elderly patients with chronic respiratory conditions and those on corticosteroid treatment. Infections in HIV and SOT patients have practically disappeared. Pulmonary involvement remains the most common area to be affected. Nocardiosis caused by N. farcinica is apparently a risk factor for poor clinical outcome., (Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.)

Published
2021
Full Text
View/download PDF

5. A multicentre analysis of Nocardia pneumonia in Spain: 2010-2016.

Author

Ercibengoa M, Càmara J, Tubau F, García-Somoza D, Galar A, Martín-Rabadán P, Marin M, Mateu L, García-Olivé I, Prat C, Cilloniz C, Torres A, Pedro-Botet ML, Ardanuy C, Muñoz P, and Marimón JM

Subjects
Adult, Aged, Aged, 80 and over, Amikacin pharmacology, Anti-Bacterial Agents pharmacology, Female, Humans, Linezolid pharmacology, Male, Middle Aged, Nocardia classification, Nocardia drug effects, Nocardia genetics, Nocardia Infections epidemiology, Nocardia Infections immunology, Pneumonia, Bacterial epidemiology, Pneumonia, Bacterial immunology, Retrospective Studies, Spain epidemiology, Trimethoprim, Sulfamethoxazole Drug Combination, Young Adult, Nocardia isolation & purification, Nocardia Infections microbiology, Pneumonia, Bacterial microbiology
Abstract

Objective: To analyse all cases of Nocardia pneumonia occurring between 2010 and 2016 in five Spanish hospitals., Methods: This was a retrospective observational analysis of clinical and microbiological data collected from 55 cases of Nocardia pneumonia., Results: There were one to 20 cases per hospital and six to nine cases per year. Chronic obstructive pulmonary disease, bronchiectasis, and asthma were the main predisposing underlying respiratory conditions. Thirty-four patients were receiving systemic and/or inhaled corticosteroids prior to infection, eight had neoplasia, and six had haematological malignancies. Clinical and radiological findings were common to pneumonia of other infectious aetiologies, except for the frequent presence of nodules and cavitation. Overall, the 1-year mortality was high (38.2%), and mortality was directly related to the pulmonary disease in 15 patients (27.3%). The most frequently identified species were N. cyriacigeorgica (n=21), N. abscessus (n=8), and N. farcinica (n=5). All Nocardia isolates were susceptible to linezolid and all but two were susceptible to amikacin and trimethoprim-sulfamethoxazole., Conclusions: Nocardia pneumonia-associated mortality remains high, probably because of the debilitated status of patients in whom this pathogen is able to cause pulmonary infection., (Copyright © 2019 The Author(s). Published by Elsevier Ltd.. All rights reserved.)

Published
2020
Full Text
View/download PDF

6. Guideline for dialysate quality of Spanish Society of Nephrology (second edition, 2015).

Author

Pérez-García R, García Maset R, Gonzalez Parra E, Solozábal Campos C, Ramírez Chamond R, Martín-Rabadán P, Sobrino Pérez PE, Gallego Pereira O, Dominguez J, de la Cueva Matute E, and Ferllen R

Subjects
Drug Packaging, Drug Storage standards, Endotoxins analysis, Filtration, Humans, Nephrology, Societies, Medical, Spain, Water Microbiology, Water Pollution, Water Purification, Hemodialysis Solutions standards, Water Quality
Abstract

A Best Practice Guideline about Dialysis fluid purity was developed under the leadership of the Spanish Society of Nephrology in 2004. The second edition revised Guideline considered new evidences and International Standard. The Guideline has established recommendations for standards for preparing dialysate: water, concentrates and hemodialysis proportioning systems. This Guideline is based on the ISO13959, European Pharmacopoeia, the Real Farmacopea Española, the AAMI Standards and Recommended Practices, European Best Practice Guidelines for Haemodialysis, literature reviews, according to their level of evidence, and the opinion of the expert Spanish group. Two levels of quality of water were defined: purified water and high purified water (ultra pure) and for dialysate: ultra pure dialysate. Regular use of ultra pure dialysate is recommended for all type of hemodialysis to prevent and delay the occurrence of complications: inflammation, malnutrition, anaemia and amiloidosis. Water, concentrates and dialysate quality requirements are defined as maximum allowable contaminant levels: chemicals (4.1.2), conductivity, microbial and endotoxins (4.1.1): Monitoring frequency, maintenance and corrective actions were specified. Methods of sampling and analysis were described in appendix (anexos). For microbiological monitoring, R2A medium is recommended, incubated during 7-14 days at a temperature of 17-23°C. The dialysate quality assurance process involves all dialysis staff members and requires strict protocols. The physician in charge of hemodialysis has the ultimate responsibility for dialysate quality. All suggestions and questions about this Guideline are wellcome to www.senefro.org., (Copyright © 2016 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. All rights reserved.)

Published
2016
Full Text
View/download PDF

7. Application of real-time PCR for the detection of Strongyloides spp. in clinical samples in a reference center in Spain.

Author

Saugar JM, Merino FJ, Martín-Rabadán P, Fernández-Soto P, Ortega S, Gárate T, and Rodríguez E

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Animals, Base Sequence, Child, Child, Preschool, Feces parasitology, Female, Helminthiasis epidemiology, Helminthiasis parasitology, Humans, Immunocompromised Host, Intestinal Diseases, Parasitic epidemiology, Intestinal Diseases, Parasitic parasitology, Male, Middle Aged, Molecular Sequence Data, Sensitivity and Specificity, Spain epidemiology, Strongyloides isolation & purification, Strongyloides stercoralis genetics, Strongyloides stercoralis isolation & purification, Strongyloidiasis epidemiology, Strongyloidiasis parasitology, Young Adult, Helminthiasis diagnosis, Intestinal Diseases, Parasitic diagnosis, RNA, Ribosomal, 18S analysis, Real-Time Polymerase Chain Reaction methods, Strongyloides genetics, Strongyloidiasis diagnosis
Abstract

Strongyloidiasis is one of the major intestinal helminthic infections in humans with a worldwide distribution, affecting especially tropical and subtropical regions. This disease can occur without any symptoms or as a potentially fatal hyperinfection or disseminated infection. Definitive diagnosis of Strongyloides stercoralis infection relies mainly on demonstration of larvae in stool, but at present there is no gold standard for this diagnosis. Our main objective was to evaluate a real-time PCR targeting the 18S rRNA gene of Strongyloides spp. and to compare it with routine parasitological methods. DNA from Strongyloides venezuelensis was used to optimize PCR protocols obtaining an analytical sensitivity of 0.1 pg of parasite DNA per sample. Sensitivity and specificity of real-time PCR on fecal samples from 231 patients screened for suspected strongyloidiasis attending two hospitals in Madrid were 93.8% and 86.5%, respectively. No significant differences were found when comparing Ct-values of positive PCR between parasitological positive and negative samples. This study showed that real-time PCR is an effective tool for diagnosing strongyloidiasis and could be applied in association with parasitological methods in epidemiological studies in endemic areas. It would be also important to assess its performance in immunocompromised populations who are at risk of fatal disease., (Copyright © 2014 Elsevier B.V. All rights reserved.)

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results